14 October 2026
14 October 2026
The Independent Data Monitoring Committee reviewed safety data from all 161 patients enrolled in the trial.
Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets.
The planned facility, designated as the Translational Hub for THRIVE, will focus on the development, validation, and adoption of NAMs.
The double-blind, randomised study evaluated 363 adult patients across 24 clinical centres in China.
The feasibility study is planned to enrol up to 30 patients across multiple centres in the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
